Development of Therapeutic Products for Antibiotic Resistant Bacteria
$9,407,873N01FY2024AINIH
Venatorx Pharmaceuticals, Inc., Malvern PA
Investigators
Abstract
To support the advanced development of candidate therapeutics for biodefense pathogens or emerging infectious diseases. The supported research and development activities will progress the therapeutic product development and may include lead optimization, candidate selection, preclinical and IND enabling studies, Chemistry, Manufacturing, and Controls (CMC), IND submission, clinical safety and efficacy assessment.
View original record on NIH RePORTER →